Davita Inc vs Stitch Fix Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Stitch Fix Inc trades at $2.74 (market cap $365.41M). The key difference: Davita Inc is far larger — about 30.9× Stitch Fix Inc's market cap, and Davita Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Stitch Fix Inc for 31 Days on average.
| DVA | SFIX | |
|---|---|---|
Market Cap | $11.28B | $365.41M |
Volume | 650,294 | 3,317,935 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $5.64 |
52-Week Low | $103.87 | $2.16 |
Typical Hold Time | 113 Days | 31 Days |
Enterprise Value | $24.00B | $261.21M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Stitch Fix (SFIX) trades at $2.73, up 2.25% today, showing recent earnings beats but facing bearish technical signals. The company reported improved financials with narrowing losses (-$28.74M net income in 2025 vs -$129M in 2024) and stable $1.27B revenue, though negative cash flow and weak FY27 guidance weigh on sentiment. Analyst consensus is mixed with 24% Buy ratings but a $3.40 price target suggesting 25% upside.
Outlook remains challenging with ongoing profitability concerns and legal investigations creating headwinds. The stock offers speculative appeal given low P/S ratio and AI-driven growth initiatives, but execution risks and competitive pressures require careful monitoring. Near-term performance hinges on reversing active client declines and achieving sustainable EBITDA positivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →